Որոնման արդյունքները - Keystone, Edward C
- Ցուցադրվում են 1 - 20 արդյունքները 40
- Գնացեք Հաջորդ էջ
-
1
Modified Disease Activity Score at 3 Months Is a Significant Predictor for Rapid Radiographic Progression at 12 Months Compared With Other Measures in Patients With Rheumatoid Arth... Movahedi, Mohammad, Weber, Deborah, Akhavan, Pooneh, Keystone, Edward C.
Հրապարակվել է 2020Տեքստ -
2
-
3
Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study Haraoui, Boulos, Cividino, Alfred, Stewart, Jacqueline, Guérette, Benoît, Keystone, Edward C
Հրապարակվել է 2011Տեքստ -
4
Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials Keystone, Edward C, Ahmad, Harris A, Yazici, Yusuf, Bergman, Martin J
Հրապարակվել է 2020Տեքստ -
5
-
6
Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis Keystone, Edward C, Breedveld, Ferdinand C, Kupper, Hartmut, Li, Yihan, Florentinus, Stefan, Sainsbury, Iain
Հրապարակվել է 2018Տեքստ -
7
Primary and secondary non-response: in need of operational definitions in observational studies Vallejo-Yagüe, Enriqueta, Keystone, Edward C, Kandhasamy, Sreemanjari, Micheroli, Raphael, Finckh, Axel, Burden, Andrea Michelle
Հրապարակվել է 2021Տեքստ -
8
The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in... Pope, Janet E, Haraoui, Boulos, Thorne, J Carter, Vieira, Andrew, Poulin-Costello, Melanie, Keystone, Edward C
Հրապարակվել է 2014Տեքստ -
9
Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometry Mahendran, Shalini M., Keystone, Edward C., Krawetz, Roman J., Liang, Kun, Diamandis, Eleftherios P., Chandran, Vinod
Հրապարակվել է 2019Տեքստ -
10
p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis Yamanishi, Yuji, Boyle, David L, Green, Douglas R, Keystone, Edward C, Connor, Alison, Zollman, Susan, Firestein, Gary S
Հրապարակվել է 2005Տեքստ -
11
-
12
Multiparameter Phospho-Flow Analysis of Lymphocytes in Early Rheumatoid Arthritis: Implications for Diagnosis and Monitoring Drug Therapy Galligan, Carole L., Siebert, Janet C., Siminovitch, Katherine A., Keystone, Edward C., Bykerk, Vivian, Perez, Omar D., Fish, Eleanor N.
Հրապարակվել է 2009Տեքստ -
13
Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials Combe, Bernard, Furst, Daniel E., Keystone, Edward C., van der Heijde, Désirée, Luijtens, Kristel, Ionescu, Lucian, Goel, Niti, Emery, Paul
Հրապարակվել է 2016Տեքստ -
14
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol pl... Strand, Vibeke, Mease, Philip, Burmester, Gerd R, Nikaï, Enkeleida, Coteur, Geoffroy, van Vollenhoven, Ronald, Combe, Bernard, Keystone, Edward C, Kavanaugh, Arthur
Հրապարակվել է 2009Տեքստ -
15
Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial Conaghan, Philip G, Emery, Paul, Østergaard, Mikkel, Keystone, Edward C, Genovese, Mark C, Hsia, Elizabeth C, Xu, Weichun, Rahman, Mahboob U
Հրապարակվել է 2011Տեքստ -
16
A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy Kremer, Joel M., Emery, Paul, Camp, Heidi S., Friedman, Alan, Wang, Li, Othman, Ahmed A., Khan, Nasser, Pangan, Aileen L., Jungerwirth, Steven, Keystone, Edward C.
Հրապարակվել է 2016Տեքստ -
17
Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled S... Wells, Alvin F., Jia, Bochao, Xie, Li, Valenzuela, Guillermo J., Keystone, Edward C., Li, Zhanguo, Quebe, Amanda K., Griffing, Kirstin, Otawa, Susan, Haraoui, Boulos
Հրապարակվել է 2021Տեքստ -
18
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients van Vollenhoven, Ronald F, Emery, Paul, Bingham, Clifton O, Keystone, Edward C, Fleischmann, Roy M, Furst, Daniel E, Tyson, Nicola, Collinson, Neil, Lehane, Patricia B
Հրապարակվել է 2013Տեքստ -
19
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis Smolen, Josef S., Kang, Young Mo, Yoo, Wan-Hee, Emery, Paul, Weinblatt, Michael E., Keystone, Edward C., Genovese, Mark C., Myung, Gihyun, Baek, Inyoung, Ghil, Jeehoon
Հրապարակվել է 2020Տեքստ -
20
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b... Cohen, Stanley B, Pope, Janet, Haraoui, Boulos, Mysler, Eduardo, Diehl, Annette, Lukic, Tatjana, Liu, Shixue, Stockert, Lori, Germino, Rebecca, Menon, Sujatha, Shi, Harry, Keystone, Edward C
Հրապարակվել է 2021Տեքստ